Navigation Links
Cytopia Commences Second Phase II Study in Brain Cancer
Date:9/4/2008

MELBOURNE, Australia, Sept. 4 /PRNewswire/ -- Cytopia Limited (ASX: CYT) today announced that it is commencing enrolment for its Phase Ib/II study of CYT997, the company's novel vascular-disrupting anticancer agent, in patients with an aggressive form of brain cancer known as glioblastoma multiforme (GBM).

The GBM clinical trial is the first Phase II efficacy study in highly vascular, solid tumor indications for the company and the second in its suite of Phase II studies designed to investigate the anticancer activity of CYT997. Patient recruitment to the study will now commence, following regulatory approval in Australia and the United States.

The clinical study will investigate the activity of CYT997 in combination with two other marketed anticancer agents in approximately 30 patients at a number of clinical centres in Australia and overseas. Dr Jason Lickliter, Director of Oncology at the Frankston Hospital, will be Study Chairman for the program.

GBM is currently treated by surgical resection, and/or radiation and chemotherapy. Despite these treatments, the condition recurs in most patients, leading to a poor prognosis and median survival of less than 12 months. GBM tumors are highly vascular and heavily dependent on their own abnormal blood supply for growth, rendering them potentially susceptible to destruction by an anti-vascular agent such as CYT997.

The following table provides a summary of the key aspects of the Phase II GBM trial.

Name of trial A Phase Ib/II Study of CYT997 in Combination with

Carboplatin and Etoposide in Relapsed Glioblastoma

Multiforme (CCL08001).

Primary endpoints Assess safety and tolerability of escalating doses

of CYT997 given in combination with standard

carboplatin and etoposide therapy (Ph Ib), and

estimation of progress
'/>"/>

SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
2. Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
3. Release of Cytopia Abstract for CYT997 Oral Presentation at American Society of Clinical Oncology
4. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
5. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
6. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
7. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
8. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
9. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
10. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
11. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
(Date:1/15/2014)... Medical is very pleased to announce the appointment of Mr. ... Officer.  Mark was promoted from his current role of Chief ... facilities in Massachusetts , Mississippi ... in 2012 with 20+ years of broad-based operations, sales, engineering ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Mich. , May 19 Stryker Corporation (NYSE: ... has informed the Company that the actions undertaken to address issues raised ... , , , ... Warning Letter from FDA regarding compliance with certain quality system requirements at ...
... SAN FRANCISCO, Calif. , May 19 ... studies was published in The Lancet on ... elevated levels of lipoprotein-associated phospholipase A2 (Lp-PLA2), a vascular-specific ... coronary heart disease similar in magnitude to that with ...
Cached Medicine Technology:Stryker Announces Resolution of Two FDA Warning Letters 2Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment 2Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment 3
(Date:4/17/2014)... vaccine brands for children may not be the most ... factors when choosing vaccines, driving the market toward what ... new study by University of Illinois researchers. , "The ... numerous factors," says Sheldon H. Jacobson, a co-author of ... of mathematics at the U. of I. "In an ...
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
(Date:4/17/2014)... older Americans suffer from depression, often brought on by ... a project that followed the lives of thousands ... that Internet use among the elderly can reduce the ... "That,s a very strong effect," said Shelia Cotten, a ... media who led the project. "And it all has ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit organization ... published a comprehensive review today examining the current state ... The review calls for improved global surveillance strategies to ... recent outbreak of Ebola in West Africa that has ... of Guinea and Liberia. According to the World ...
(Date:4/17/2014)... not uncommon these days to find a colored ribbon representing ... breast cancer. But what color ribbon does one think of ... designated color, for many suffering from the disease, black may ... University study consisting of lung cancer patients, primarily smokers between ... more light on the stigma often felt by these patients, ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Unraveling the 'black ribbon' around lung cancer 2
... UL joins the Field Museum for World Water Day March ... world leader in product safety testing services, will launch its ... of the Field Museum, 1400 S. Lake Shore Drive in ... 22, 2009. As part of the organization,s century-long commitment ...
... Foundation restore music programs in public schools and fuel discovery of ... 19 Abbott ( NYSE: ... Nutrition Bars is launching the " live.cr eat ... The Music Foundation to help restore instrumental music programs in ...
... 19 Endo Pharmaceuticals (Nasdaq: ENDP ) today ... wholly owned subsidiary, BTB Purchaser Inc., for all of the ... IDEV ). American Stock Transfer & Trust Company, ... as of 5 p.m., New York City time, on March ...
... full line up of American-built pedicure spas at the ... Care & Spa Show, March 28th-30th at McCormick Place, ... health regulations and concern among many Americans of receiving ... USA is proud to raise the bar against cross ...
... Pharmaceuticals (NYSE: VRX ) today announced that ... of President, Valeant Pharmaceuticals International, effective March 10, 2009. ... for overseeing the Dow Services business, corporate business development ... and will be a member of Valeant,s Executive Management ...
... Inc. (OTC Bulletin Board : ANPG), reported today that it plans ... Stock, which it currently anticipates will be in the range of ... is approved, each holder of Anpath,s Common Stock on the date ... receive one share of new Common Stock in exchange for every ...
Cached Medicine News:Health News:World Water Day 2009 Marks Launch of UL's Yearlong Commitment to Water Quality and Conservation Education 2Health News:World Water Day 2009 Marks Launch of UL's Yearlong Commitment to Water Quality and Conservation Education 3Health News:Photo: ZonePerfect(R) Nutrition Bars Launches Nationwide Tour With VH1 Save The Music Foundation to Nourish Arts, America's Schools 2Health News:Photo: ZonePerfect(R) Nutrition Bars Launches Nationwide Tour With VH1 Save The Music Foundation to Nourish Arts, America's Schools 3Health News:Photo: ZonePerfect(R) Nutrition Bars Launches Nationwide Tour With VH1 Save The Music Foundation to Nourish Arts, America's Schools 4Health News:Photo: ZonePerfect(R) Nutrition Bars Launches Nationwide Tour With VH1 Save The Music Foundation to Nourish Arts, America's Schools 5Health News:Photo: ZonePerfect(R) Nutrition Bars Launches Nationwide Tour With VH1 Save The Music Foundation to Nourish Arts, America's Schools 6Health News:Endo Pharmaceuticals Announces Successful Completion of Tender Offer for Indevus Pharmaceuticals 2Health News:Clean Spa Technologies USA Adopts GeniJet(TM) Plus Hydrotherapy System with Built-In Ionizer - Sets Industry Standard for Pedicure Hygiene 2Health News:Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International 2Health News:Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International 3Health News:Anpath Group, Inc. Announces Intent To Seek Shareholder Approval for a Reverse Split of Its Common Stock 2
... highly effective immobilization of the cervical and ... comfort that makes it well tolerated by ... in going from a stand-alone cervical collar, ... to a four-post orthosis. For these reasons, ...
... Until now, laborious custom fabrication was required ... was limited and modifications in response to ... cumbersome.,The GunSlinger evolved from two years of ... teaching hospital. This orthosis can be quickly ...
... is designed for the management of ... fractures. The lightweight anatomical design achieves ... for optimal control of humeral segments ... shoulder and elbow joints. In addition ...
... therapeutic benefits of controlled compression and cold, ... pain. The anatomically designed cuff provides complete ... can be ordered with an extra long ... circumferences.,All Cryo/Cuffs can be ordered as a ...
Medicine Products: